 This Phase I, nonrandomized, open-label study will enroll up to seven healthy male subjects who meet all of the inclusion and none of the exclusion criteria. Subjects will receive 100 20 μCi of 3H BMS747158. Subjects will undergo blood, urine, and fecal collections to evaluate 3H activity for a minimum of 7 days post-dose. Safety will be assessed by monitoring of adverse events AEs, vital signs, physical examinations, clinical laboratory tests, and electrocardiograms ECGs.This Phase I, nonrandomized, open-label study will enroll up to seven healthy male subjects who meet all of the inclusion and none of the exclusion criteria. Subjects will receive 100 20 μCi of 3H BMS747158. Subjects will undergo blood, urine, and fecal collections to evaluate 3H activity for a minimum of 7 days post-dose. Safety will be assessed by monitoring of adverse events AEs, vital signs, physical examinations, clinical laboratory tests, and electrocardiograms ECGs. 